The analysis of the samples of 94 breast cancer patients using immunoblotting revealed that the AKT inhibitors had the ability to reduce the basal AGR2 levels and attenuate the induction of AGR2 by tamoxifen, which was more pronounced in cells that were treated with the combination of tamoxifen and AKT inhibitors [74]. The gene discussed is AGR2; the disease is breast carcinoma.